PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.71%
G&A growth while AGEN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
-38.54%
Other expenses reduction while AGEN shows 0.00% growth. Joel Greenblatt would examine efficiency.
25.41%
Operating expenses growth while AGEN reduces costs. John Neff would investigate differences.
25.41%
Total costs growth while AGEN reduces costs. John Neff would investigate differences.
-10.64%
Interest expense reduction while AGEN shows 10.19% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
EBITDA decline while AGEN shows 7.19% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Operating income decline while AGEN shows 6.38% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
353.66%
Other expenses growth while AGEN reduces costs. John Neff would investigate differences.
100.00%
Income change of 100.00% while AGEN is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
-610.74%
Both companies reducing tax expense. Martin Whitman would check patterns.
610.74%
Net income growth exceeding 1.5x AGEN's 3.47%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
609.26%
EPS growth exceeding 1.5x AGEN's 6.25%. David Dodd would verify competitive advantages.
609.26%
Diluted EPS growth exceeding 1.5x AGEN's 6.25%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.